8-K
filed March 20, 2026, 7:59 PM ET
ticker CV
CIK 0001378325
other material
confidence high
sentiment neutral
materiality 0.70
CapsoVision closes $14M private placement; reports preliminary FY2025 revenue of $13.6M
CapsoVision, Inc
- Raised $14M gross via 2.87M shares at $4.883 (5% discount to March 16 close); closed March 16, 2026.
- Preliminary Q4 2025 revenue $3.9M; full-year 2025 revenue $13.6M; cash & equivalents ~$10.1M as of Dec. 31, 2025.
- Abandoned first-gen CapsoCam Colon 510(k); prioritizing second-gen with improved imaging; pivotal study enrolling ~800 patients; over 500 enrolled; expects 510(k) submission in Q3 2026.
- Breakthrough Device Designation for CapsoCam UGI denied in Jan 2026; plans to resubmit after ~90-patient study starting Q2 2026.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
CapsoVision, Inc reported preliminary financial results for fourth quarter and full year ended December 31, 2025.
- Period
- fourth quarter and full year ended December 31, 2025
- Result
- preliminary results
Exact text from the filing
On March 20, 2026, the Company issued a press release announcing certain of its preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.99
CapsoVision, Inc issued 2,867,089 shares of common stock to selected accredited investors for $4.883 per Share.
- Security
- common stock
- Shares
- 2,867,089 shares
- Purchaser
- selected accredited investors
- Consideration
- $4.883 per Share
Exact text from the filing
to the Investors in the Private Placement an aggregate of 2,867,089 shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), at $4.883 per Share, which represents a 5% discount to the March 16th closing price, as per the terms of the agreement. The Securities Purchase Agreement contains customary representations
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CapsoVision, Inc entered into Securities Purchase Agreement with selected accredited investors (the "Investors") valued at approximately $14 million (effective 2026-03-16).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- selected accredited investors (the "Investors")
- Value
- approximately $14 million
- Effective
- 2026-03-16
Exact text from the filing
On March 16, 2026, CapsoVision, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with selected accredited investors (the “Investors”), for the purposes of raising approximately $14 million in aggregate gross proceeds for the Company (the “Private Placement”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CapsoVision, Inc entered into Registration Rights Agreement with the Investors (effective 2026-03-16).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the Investors
- Effective
- 2026-03-16
Exact text from the filing
In connection with the Private Placement, the Company entered into a registration rights agreement, dated March 16, 2026 (the “Registration Rights Agreement”), with the Investors, pursuant to which, among other things, the Company will (i) prepare and file with the Securities and Exchange Commission (the “SEC”) a registration statement to register for resale the Shares within 90 days after the closing of the Private Placement, and (ii) use commercially reasonable efforts to have such registration statement declared effective as soon as reasonably practicable following the filing thereof with the SEC.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.